Xenon Pharmaceuticals: Q3 Earnings Insights

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:01 PM. Here’s what…

Xenon Pharmaceuticals (NASDAQ:XENE) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:01 PM.

Here’s what investors need to know about the announcement.

Earnings

Xenon Pharmaceuticals beat estimated earnings by 5.19%, reporting an EPS of $-0.73 versus an estimate of $-0.77.

Revenue was down $132 thousand from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.02 which was followed by a 8.29% increase in the share price the next day.

Here’s a look at Xenon Pharmaceuticals’s past performance:

Quarter Q2 2023 Q1 2023 Q4 2022 Q3 2022
EPS Estimate -0.70 -0.62 -0.58 -0.52
EPS Actual -0.72 -0.63 -0.57 -0.57
Revenue Estimate 400K 570K 2.28M 3.02M
Revenue Actual 0 0 0 132K

To track all earnings releases for Xenon Pharmaceuticals visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue And Provides Corporate Updates; Sees Q4 Revenue $69M-$71M Vs $68.27M Est.; FY23 Revenue $178M-$180M Vs $185.4M Est.; LIVMARLI Net Products Sales Of $141M-143M Expected For 2023

- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited- LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89%

MIRM